IngredientsFenuside (also rendered as fenusides, fenuside saponins, or commercially as Fenuside™) is the collective term used in the dietary supplement industry to denote a class of furostanol saponins — steroidal, bidesmosidic glycosides — extracted from the seeds of Trigonella foenum-graecum L. (fenugreek). Fenuside is a bioactive compound derived from the seeds of the fenugreek plant (Trigonella foenum-graecum), a botanical traditionally used in various culinary and medicinal applications across cultures, particularly in South Asia and the Mediterranean. Fenuside is identified as a furostanol saponin and is credited with many of the plant's beneficial properties.
The NIH Office of Dietary Supplements Dietary Supplement Label Database (DSLD) lists Fenuside under related label terms including: Fenuside; Fenusides; Fenuside saponins; Fenuside™; Fenusterols; and Fenusterols®. In commercial extracts, the term is most commonly associated with the standardized trademark ingredient Testofen®, developed by Gencor Pacific, which is a fenugreek seed extract standardized to 50% Fenuside™ saponins.
Chemically, furostanol saponins share a specific structural arrangement. Fenugreek seeds contain saponins in the form of furostanol saponins. Furostanol saponins may be defined as bidesmosidic saponins which have two sugar chains, with one bonded at C3 and one attached through an ether linkage at C26 with a D-glucose. Fenugreek seeds have been found to contain at least a dozen different saponins. The main saponin is diosgenin and its isomers yamogenin, gitogenin, and tigogenin. Other furostanols include smilagenin, sarsasapogenin, neotigenin, yuccagenin, lilagenin, and neogitogenin.
Advanced phytochemical studies have revealed considerable complexity within this saponin fraction. An ultra-performance liquid chromatography coupled with a hybrid quadrupole time-of-flight tandem mass spectrometry method established to rapidly identify and guide the isolation of target saponins from fenugreek seeds detected a total of forty-six furostanol saponins, of which twenty compounds were predicted to be new. A separate analytical study by HPLC-ELSD-ESI-MS similarly revealed a total of 26 furostanol saponins, of which 24 were tentatively identified. The sapogenin aglycone most central to fenuside activity is diosgenin, which carries the IUPAC name (25R)-5-spirosten-3β-ol. Diosgenin, a steroid sapogenin constituent of fenugreek seeds, is a precursor of steroid hormones, such as progesterone, and anti-inflammatory steroids, such as cortisone.
Trigonella foenum-graecum (sicklefruit fenugreek) belongs to the pea family (Fabaceae). It is native to India and northern Africa and is one of the oldest medicinal plants in continuous use. The fenugreek plant grows up to 60 cm in height, and its seeds are golden-yellow rhomboidal-shaped. Though fenugreek is more commonly known for its seeds, the leaves and stem have also been reported to have medicinal uses. However, commercially standardized fenuside extracts are derived specifically from the dried seeds.
Fenuside-containing products reach the market primarily as standardized seed extracts rather than as isolated individual saponins. Fenugreek seed extract (Trigonella foenum-graecum) standardized to 50% fenusides is a concentrated botanical ingredient derived from the seeds of the fenugreek plant. This extract is rich in furostanolic saponins, specifically fenusides, which are the primary bioactive compounds associated with the plant's physiological effects. In the food and food supplement industry, this standardized extract is utilized for its profile of secondary metabolites, including saponins, flavonoids, and alkaloids.
Common preparations include:
Trigonella foenum-graecum has been utilized as a medicinal plant in Central Asia since approximately 4000 BC. The benefits and medicinal purposes have been found reported in one of the oldest medicinal documents, the Ebers papyrus. It was used by the Harappa civilization in India around 2000 BC and was also important in ancient Egypt, where it was used for incense and embalming.
Ancient Egyptians used fenugreek to ease childbirth, stimulate lactation, and in embalming practices. Hippocrates praised its soothing properties, and Romans used it in treatments for fevers, respiratory conditions, and wound healing. In ancient Rome, fenugreek was used to aid labour, period cramps, and as a tonic for metabolism.
The ancient Greeks also valued the medicinal properties of fenugreek and used it to treat a range of ailments, including indigestion and bronchitis. During the first Jewish-Roman war, it was used by the physician of the Roman general Pompey to treat wounds.
Among Arab scholars and in Islamic medical tradition, fenugreek held particular significance. It was studied at the School of Salerno by Arab physicians and had great importance in Hadith. According to Qasim Bin Abdul Rehman, Rasulullah said, "Seek cure by (using) fenugreek."
In Ayurvedic and Chinese medicine, T. foenum-graecum L. has a long history of medical uses as a demulcent, lactation stimulant, and laxative. In Ayurvedic medicine, fenugreek is considered a "rasayana" herb — that is, it is said to promote general health and well-being. In Ayurveda, fenugreek is used to stimulate digestion, balance blood sugar, and enhance reproductive health. Its warming nature is said to ignite "Agni," or digestive fire, making it an effective remedy for sluggish metabolism and gas.
In Ayurvedic and Unani systems, fenugreek has been a trusted remedy for balancing blood sugar, soothing inflammation, and bolstering overall vitality.
In TCM, fenugreek is known as "Hu Lu Ba," where it is prescribed for treating kidney weakness, painful menstruation, and male impotence. In traditional Chinese medicine, fenugreek was used to treat a variety of ailments, including fever, vomiting, and diarrhea. Traditional texts in Ayurveda, Chinese, Arabic, Greek, and Latin pharmacopoeias extensively document its medicinal virtues.
Historically, preparations containing fenugreek and its active compounds were used to address digestive complaints, promote women's health, and support lactation in nursing mothers. In ancient Egypt, fenugreek was used to boost milk production in breastfeeding mothers, and modern Egyptian women still consume these seeds to alleviate menstrual cramps. In the Indian subcontinent, fenugreek was being consumed as a lactation stimulant and condiment.
It bears noting that in traditional contexts, these uses pertained to whole seeds or simple decoctions, not to concentrated, standardized fenuside extracts — the latter being a modern commercial development intended to deliver higher saponin content.
Fenugreek seeds contain a broad phytochemical profile, and fenuside extracts are standardized to concentrate the saponin fraction. Active compounds of fenugreek seeds include dietary fiber (50%) comprising soluble fiber (30%) (predominantly galactomannan) and insoluble fiber (20%), saponins (4%–8%; mainly diosgenin), alkaloids (1%, mainly trigonelline), and 4-hydroxyisoleucine.
Fenugreek (Trigonella foenum-graecum) seeds contain mucilage, quercetin, luteolin, genistein, vitexin, trigonelline, 4-hydroxyisoleucine, sotolon, diosgenin, luteolin, protodioscin, and several other pharmacologically active saponins and isoflavones.
The most comprehensively studied bioactive compounds present in fenugreek are diosgenin, 4-hydroxyisoleucine (4-OH-Ile), and the soluble dietary fiber fraction of fenugreek seeds. In the context of fenuside-standardized extracts, the saponin fraction is primary:
The mechanisms by which fenuside-standardized fenugreek extracts exert their effects are partly understood, with evidence coming primarily from in vitro and animal models, and increasingly from clinical observations. Multiple pathways have been proposed and investigated:
In sports nutrition, the anabolic effects of the furostanol saponins are considered potentially useful to induce increased testosterone levels, which in turn increase the deposition of protein in the muscles, leading to increased muscle mass and strength. One proposed mechanism is that fenuside saponins may act as precursors or modulators for steroidogenesis, given that diosgenin — the primary aglycone — is structurally related to cholesterol-derived steroid hormones. Diosgenin, a steroid sapogenin constituent of fenugreek seeds, is a precursor of steroid hormones such as progesterone, and anti-inflammatory steroids such as cortisone. The exact upstream and downstream signaling involved in testosterone modulation in humans remains incompletely characterized. The mechanism of action is not specifically known, but may be related to phytoestrogens or diosgenin.
It is generally agreed that fenugreek bioactives can mediate distinct physiological and metabolic responses, including protection of the pancreatic and hepatic function, leading to improved glucose metabolism and normalization of blood glucose levels. Potential mechanisms include delayed gastric emptying, inhibition of intestinal glucose absorption, insulinotropic activity, and improved gut microbiota. However, the exact effectors and molecular pathways remain to be ascertained.
Specifically, regarding glucose-lowering: The mechanisms of action attributed to diosgenin in ameliorating experimentally induced diabetes include restoration of pancreatic β-cells, downregulation of the enzymes involved in hepatic gluconeogenesis and glucose export, and induction of hepatoprotective and antioxidant enzymes.
An additional mechanism involves GLP-1: Fenugreek has been studied for its effects on glucagon-like peptide-1 (GLP-1), a hormone involved in regulating blood sugar levels and appetite. GLP-1 works in weight loss through various effects, including suppressing hunger and inducing satiety, slowing gastric emptying, enhancing insulin secretion, and lowering blood glucose levels.
Network pharmacology modeling has further identified targets: 19 active compounds from fenugreek and 71 key diabetes-related targets were identified through network pharmacology analysis. Molecular docking and simulation results suggest diosgenin, luteolin, and quercetin act against diabetes via regulation of the genes ESR1, CAV1, VEGFA, TP53, CAT, AKT1, IL6, and IL1. Pathway enrichment analysis revealed that the anti-diabetic effect of fenugreek was regulated by the AGE-RAGE and NF-κB signaling pathways, and is mainly associated with anti-oxidative stress, anti-inflammatory response, and β-cell protection.
The seeds of fenugreek are known to exert hypocholesterolemic effects. In experiments conducted over the last decade, several groups of researchers demonstrated that the hypocholesterolemic effects of fenugreek resided in the fat-free fraction, more precisely, in the saponin-rich sub-fraction. Saponins interfere with the intestinal reabsorption of bile acids, promoting their fecal excretion and thereby reducing circulating cholesterol. Some components of fenugreek like saponins and mucilages have shown hypocholesterolemic effects in animal studies. Mucilage, tannins, pectin, and hemicellulose from fenugreek bind to bile acids to reduce cholesterol and fat absorption.
Diosgenin and 4-hydroxyisoleucine exert beneficial effects on several physiological markers including glucose tolerance, inflammation, insulin action, liver function, blood lipids, and cardiovascular health. Fenugreek's anti-inflammatory effects are thought to involve inhibition of NF-κB signaling, as determined by computational and in vitro studies.
The great majority of clinical research has been conducted using standardized fenugreek seed extracts including those standardized for fenuside content (i.e., 50% furostanol saponins), rather than isolated fenuside compounds. Evidence is therefore best characterized as applying to fenuside-standardized fenugreek extract rather than to any single purified molecule.
Clinical evidence (men — aging males): The most widely cited clinical study on Testofen® (standardized to 50% Fenuside™) is a double-blind RCT published in the journal Aging Male. This was a double-blind, randomised, placebo-controlled trial involving 120 healthy men aged between 43 and 70 years of age. The active treatment was standardised Trigonella foenum-graecum seed extract at a dose of 600 mg/day for 12 weeks. This study examined the effect of Testofen on the symptoms of possible androgen deficiency, sexual function, and serum androgen concentrations in healthy aging males. The primary outcome measure was the change in the Aging Male Symptom questionnaire (AMS), a measure of possible androgen deficiency symptoms; secondary outcome measures were sexual function and serum testosterone. There was a significant decrease in AMS score over time and between the active and placebo groups. Sexual function improved, including number of morning erections and frequency of sexual activity. This study was funded by Gencor Pacific, the manufacturer of Testofen®.
Clinical evidence (men — physical performance): A randomised, placebo-controlled, double-blind study aimed to examine changes in muscular strength and endurance, body composition, functional threshold power, and sex hormones in response to an 8-week calisthenic programme with daily supplementation with Testofen® (fenugreek extract) or a placebo. This study, also funded by Gencor Pacific Ltd., found improvements in strength parameters and muscle mass.
Systematic review evidence: A systematic review covering seven studies with 449 participants detected measurable effects on total testosterone (SMD: 0.32) and free testosterone (SMD: 0.24).
Limitations: Multiple studies in this area have been sponsored by the ingredient manufacturer. The evidence base for testosterone-specific effects is composed largely of small trials, some without clearly matched control populations. Mechanistic pathways in humans are not fully established.
A clinical study published in the peer-reviewed journal Phytotherapy Research evaluated the effect of Libifem, a proprietary standardized extract of fenugreek seed from Gencor, on sex hormones and sexual function in women. The participants were healthy, menstruating women in stable relationships who self-reported having a low sex drive. The short-term, single-site, double-blind, randomized, and placebo-controlled study was conducted on 80 women aged 20 to 49 years. Participants were randomized to either an oral dose of Libifem at a dose of 600 mg/day or placebo over two menstrual cycles.
A standardized extract of Trigonella foenum-graecum was associated with significant increases in measures of sexual cognition, arousal, sexual behavior, sexual drive, and orgasm, according to findings published in Phytotherapy Research. The supplementation showed a significant increase in the serum levels of female sex and libido-related hormones, including estrogen and free testosterone.
A second published study using Libifem at 300 mg twice daily over two menstrual cycles found: Analysis of sex hormone levels after 8 weeks of treatment showed a significant increase in oestradiol levels in the active group compared to the placebo group. There were no significant differences in any hormones in the placebo group. There was no difference in the other markers of metabolism after treatment in either group. The results indicate that Libifem is an effective treatment to improve sexual function in otherwise healthy women and the biochemical mechanism may involve a restoration or maintenance of healthy oestradiol levels.
Limitations: Both Libifem studies were conducted at single sites, funded by Gencor Pacific, and are relatively small in sample size. The evidence for female sexual function is preliminary and based on this limited, industry-sponsored trial base.
This is among the most studied areas. Multiple meta-analyses of RCTs have examined fenugreek (including saponin-containing and whole seed preparations) on glycemic outcomes.
Meta-analysis (2014): Researchers systematically reviewed clinical trials of the effect of fenugreek intake on markers of glucose homeostasis, searching PubMed, SCOPUS, the Cochrane Trials Registry, Web of Science, and BIOSIS through November 2013. Data on change in fasting blood glucose, 2-hour postload glucose, and HbA1c were pooled using random-effects models. A total of 10 trials were identified. Fenugreek significantly changed fasting blood glucose by −0.96 mmol/l (95% CI: −1.52, −0.40; I² = 80%), 2-hour postload glucose by −2.19 mmol/l (95% CI: −3.19, −1.19; I² = 71%), and HbA1c by −0.85% (95% CI: −1.49%, −0.22%; I² = 0%) as compared with control interventions.
The considerable heterogeneity in study results was partly explained by diabetes status and dose: significant effects on fasting and 2-hour glucose were only found for studies that administered medium or high doses of fenugreek in persons with diabetes. Most of the trials were of low methodological quality. Results from clinical trials support beneficial effects of fenugreek seeds on glycemic control in persons with diabetes. However, trials with higher methodology quality using a well-characterized fenugreek preparation of sufficient dose are needed to provide more conclusive evidence.
Meta-analysis (2024, T2DM-specific): A 2024 PRISMA-guided systematic review and meta-analysis of 19 RCTs in patients with T2DM found: Fenugreek supplementation significantly reduced FPG by 20.32 mg/dL, glycated hemoglobin by 0.54%, and HOMA-IR by 0.36 in patients with T2DM. According to lipid profile, fenugreek supplementation significantly reduced total cholesterol by 33.1 mg/dL and LDL-C by 29.14 mg/dL, along with increasing HDL-C by 5.68 mg/dL in patients with T2DM.
Meta-analysis (2023, T2DM and prediabetes): After screening, a total of 10 studies (706 participants) remained in the analysis. Fenugreek significantly reduced fasting blood glucose (FBG), 2-hour postprandial glucose (2-hPG), and HbA1c, but did not significantly decrease HOMA-IR. Moreover, it significantly improved TC, TG, and HDL-C, while there were no significant differences in LDL-C and BMI.
Evidence strength: The glycemic evidence is moderate-to-consistent across multiple meta-analyses, with significant reductions in key glycemic markers. The body of literature is complicated by heterogeneous preparations (whole seed vs. extract, different doses), variable study quality, and high statistical heterogeneity in some analyses. The evidence is strongest for populations with frank type 2 diabetes at medium-to-high doses.
Various studies have shown that Trigonella foenum-graecum (fenugreek) supplementation has lipid-lowering activity, and meta-analyses have been performed to evaluate the effect of fenugreek supplementation on human serum lipid profile.
A meta-analysis of 12 RCTs (14 arms, 560 participants) searching PubMed, EMBASE, Scopus, and Cochrane through December 2019 found: A significant decrease in plasma concentrations of total cholesterol (WMD = −9.371 mg/dL; 95% CI: −15.419, −3.323, p = 0.002), triglycerides (WMD = −13.776 mg/dL; 95% CI: −26.636, −0.916, p = 0.036), and LDL-C (WMD = −6.590 mg/dL; 95% CI: −13.042, −0.137, p = 0.045), as well as an increase in plasma HDL-C (WMD = 3.501 mg/dL; 95% CI: 1.309, 5.692, p = 0.002), while body weight and body mass index were not altered.
The results of subgroup analysis showed that fenugreek reduced TG and LDL and increased HDL levels in diabetic subjects more effectively. Fenugreek supplementation significantly improved lipid profile (LDL, TG, TC, and HDL).
Evidence strength: Moderate. Lipid-lowering effects are consistent across multiple RCT meta-analyses, particularly in diabetic subjects, but are modest in absolute magnitude. High study heterogeneity and variable preparation types limit definitive conclusions.
The mechanism of action for galactagogue effects is not specifically known, but may be related to phytoestrogens or diosgenin. Not many studies have detected the presence of fenugreek bioactives in breast milk, but one study assessing the antioxidant capacity of breast milk from mothers drinking fenugreek tea failed to find a significant difference relative to placebo. Evidence to support fenugreek enhancing milk production is limited, but fenugreek tea does have preliminary evidence in support of this traditional usage.
Evidence strength: Weak. Fenugreek's galactagogue use is one of the most ancient and persistent traditional applications, but clinical evidence is limited and mechanistically unclear.
The following dosages are drawn only from the published clinical literature and should not be interpreted as recommended doses. Study populations, preparations, and durations vary significantly:
A scoping review of the adverse effects literature found: The most common adverse effect was mild gastrointestinal discomfort following oral consumption. Other reported effects included hypoglycemia, potential hypokalemia, allergic reactions, a maple syrup odor in the urine, sweat, or skin of infants and mothers, and interactions with certain medications. Fenugreek is generally considered safe, with most reported side effects being mild and self-limiting. No fatalities have been attributed to its use.
The NIH LiverTox database gives fenugreek a likelihood score of E (unlikely cause of clinically apparent liver injury). Hepatic or renal toxicity was not observed, and there were no severe adverse events associated with fenugreek despite mild gastrointestinal side effects in some studies. Fenugreek improves overall glycemic control parameters and lipid profile safely.
Fenugreek is not safe for use during pregnancy in amounts greater than those found in food; its use has been linked to increased risks of birth defects in both animals and people. Animal reproductive studies of fenugreek show evidence of antifertility effect in males and females, and fetal harm when consumed during pregnancy.
Regarding the steroidal saponin component specifically: Previously published findings on fenugreek toxicity on reproduction, fetal development, and teratogenicity establish that steroidal saponin diosgenin has been associated with reproductive defects. Consumption of fenugreek with limited doses is suggested. The underlying mechanism for reproductive toxicity induced by fenugreek's phytosteroid component, diosgenin, has been discussed.
Little is known about whether it's safe to use fenugreek in amounts greater than those found in food while breastfeeding. In a survey of nursing mothers in the United States, 85 had used fenugreek as a galactogogue and 45% reported having experienced an adverse reaction from the supplement.
Perhaps its most unusual side effect is the imparting of an odor of maple syrup to the urine, sweat, feces, and possibly breastmilk by the sotolon in fenugreek. This can mimic symptoms of maple syrup urine disease in infants exposed through breast milk and has been reported as a source of clinical concern in neonates.
Because of the high fiber content, and estrogenic and coumadin-like effects of fenugreek, it has a potential to cause herb-drug interactions, particularly if taken in high doses with antiplatelet drugs and warfarin. It can also interact with warfarin to cause bleeding. Caution should be used in giving high dosages to women with diabetes mellitus or those taking warfarin.
The additive hypoglycemic risk is clinically relevant: because fenuside-standardized extracts contribute to blood glucose lowering, concurrent use with antidiabetic medications (insulin, sulfonylureas, metformin) may increase risk of hypoglycemia.
Case reports or case series have detailed allergic reactions or hypersensitivity signs and symptoms, including ten case reports or case series reported in eight articles. Fenugreek is a member of the Fabaceae (legume) family, and cross-reactivity with other legumes including peanuts and chickpeas has been described.
The NIH Office of Dietary Supplements Dietary Supplement Label Database classifies Fenuside as a dietary supplement ingredient (Non-nutrient/non-botanical categorized ingredient on labels; related botanical listing under Trigonella foenum-graecum). No independent health claims or recommended daily intakes have been established by the FDA, EMA, EFSA, or other regulatory bodies specifically for fenuside as a discrete compound. Finished products in the United States are marketed under the Dietary Supplement Health and Education Act (DSHEA) framework, which does not require pre-market efficacy or safety proof. Dietary supplements do not require extensive pre-marketing approval from the U.S. Food and Drug Administration. Manufacturers are responsible to ensure safety, but do not need to prove the safety and effectiveness of dietary supplements before they are marketed.
Health conditions that Fenuside may help support.
Body systems that Fenuside may help support.
Go back